Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | HBB | P68871 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504353 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371134 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2370652 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL1119124 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371891 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371874 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL5828245 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2380101 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL11701621 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB | |
| SCHEMBL2371273 | 1.00 | LMNA (0.65) | LMNAMEN1KMT2ABLMHBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20030157538-A1 | Nucleic acid biosensor diagnostics | KRULL ULRICH J (CA) | 2003-08-21 | — | — | US | claimed |
| US-20130039956-A1 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | Dietz, Ulrich (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2547322-A2 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | Dietz, Ulrich (DE) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113507-A2 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | DIETZ ULRICH (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-5137929-A | Additives which stabilize hydrohalocarbon blowing agent in polyurethane and polyisocyanurate foam formulations during polymerization | ALLIED-SIGNAL INC. (US) | 1992-08-11 | — | — | US | disclosed |
| US-4961867-A | Process for preventing corrosion of metals by contacting them with compositions prepared from amino substituted pyrazines and carboxylic acids carboxylic acid anhydrides, carboxylic acid, esters or carboxylic acid halides | THE DOW CHEMICAL COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
| US-4957640-A | Corrosion prevention with compositions prepared from organic fatty amines and nitrogen-containing aromatic heterocyclic compounds | THE DOW CHEMICAL COMPANY (US) | 1990-09-18 | — | — | US | disclosed |
| US-4861884-A | OIL WELL CORROSION INHIBITOR | THE DOW CHEMICAL COMPANY (US) | 1989-08-29 | — | — | US | disclosed |
| US-4765839-A | PAVING | THE DOW CHEMICAL COMPANY (US) | 1988-08-23 | — | — | US | disclosed |
| US-4761473-A | CORROSION RESISTANCE OF OIL OR GAS WELLS | THE DOW CHEMICAL COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
| US-4035400-A | Preparation of omega-nitroalkanoic acids | TEXACO INC. (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039956-A1 | USE OF NITROCARBOXYLIC ACIDS FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF AGGRESSIVE HEALING PATTERNS | NOS1, NOS2, NOS3 | LMNA 3624/4885MEN1 4792/4885KMT2A 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.